Creyon Bio, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Creyon Bio, Inc. - overview
Established
2019
Location
Sam Diego, CA, US
Primary Industry
Pharmaceuticals
About
Based in California, US, and founded in 2019 by its CEO Chris Hart and CSO Swagatam, Creyon Bio, Inc. operates as a drug development platform. In March 2022, Creyon Bio, Inc. raised an undisclosed amount of series A funding co-led by new investors DCVC Bio and Lux Capital, with participation from other new investors Casdin Capital, Alexandria Venture Investments.
Creyon Bio operates as a drug company that provides (ribonucleic acid) RNA-based medicines and oligonucleotide-based medicines (OBMs) which are used in various respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). The company’s offerings include purpose-built datasets that feed into sophisticated machine learning models, quickly discovering design rules and engineering principles for safe and effective OBMs (Oligonucleotide-based medicines). The company plans to use the March 2022 funding to further enhance its platform, expand the team, and lay the foundations for a diverse internal pipeline.
Current Investors
Alexandria Venture Investments, Lux Capital, Casdin Capital
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.creyonbio.com
Verticals
Artificial Intelligence, Manufacturing
Company Stage
Series A
Total Amount Raised
Subscriber access only
Creyon Bio, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.